drugset
drugset / Trial / NCT02244944

Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD

NCT02244944 ↗

Phase 2 Terminated 2 enrolled Gregory Graf, PhD
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research is to gather information on the combination Zetia® (Ezetimibe) and Urso Forte® with respect to sterol balance and their effects on biomarkers of liver function in subjects with nonalcoholic fatty liver disease (NAFLD).

Timeline

Start
2014-09
Primary completion
2015-09
Completion
2015-09

Outcome

Outcome not reported

Stopped (Enrollment): “Failure to recruit”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 10 mg —
Subject Ursodeoxycholic Acid Small molecule 13 mg/kg —
Subject Ursodeoxycholic Acid Small molecule 15 mg/kg —

Indications

NAFLD1